Michael Liptay to Cyclin-Dependent Kinase Inhibitor p16
This is a "connection" page, showing publications Michael Liptay has written about Cyclin-Dependent Kinase Inhibitor p16.
Connection Strength
0.128
-
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
Score: 0.106
-
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
Score: 0.022